Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SAVEBRAIN

Financiado

Proof of principle for a first in class neuroprotective therapy in stroke and ot...

Proof of principle for a first in class neuroprotective therapy in stroke and other acute neurodegenerative conditions Stroke represents currently one of the largest – if not the largest - unmet medical need: It is the second leading cause of death and the leading cause of disability. In contrast to this high demand for effective treatments, there... ver más

30/09/2019

UNIVERSITEIT MAAST...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-09-30

ERC-PoC-2016: ERC-Proof of Concept-2016

I+D

Cerrada hace 8 años

0% 100%

4 Participantes

UNIVERSITEIT MAASTRICHT

51.90K€ | Lider

ARITEX CADING

1.19M€ | Participante

Fraunhofer

78.10K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2009-13015-C02-01 DISEÑO, SINTESIS Y EVALUACION DE FARMACOS NEUROGENICOS COMO... 242K€ Cerrado

IPT-2011-1312-900000 Desarrollo de terapias neuroprotectoras para Esclerosis Múlt... 715K€ Cerrado

PTQ-10-03816 Investigación y desarrollo de nuevos fármacos neuroprotector... 114K€ Cerrado

SAF2012-31035 NUEVOS FARMACOS PROTECTORES MITOCONDRIALES PARA EL POTENCIAL... 176K€ Cerrado

EDVance EDV2209 – a Paradigm shift in the treatment of stroke. 4M€ Cerrado

PTQ-11-04550 Nuevas terapias farmacológicas para el tratamiento de enferm... 36K€ Cerrado

Duración del proyecto: 21 meses Fecha Inicio: 2017-12-11
Fecha Fin: 2019-09-30

Líder del proyecto

UNIVERSITEIT MAASTRICHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Stroke represents currently one of the largest – if not the largest - unmet medical need: It is the second leading cause of death and the leading cause of disability. In contrast to this high demand for effective treatments, there is only one drug available, a blood-clot dissolving agent. However, this drug is marginally effective has over 30 contra-indications, and bears an extremely high risk of causing fatal bleeding that 85% of all stroke patients are not treated with it. The needed innovation would be a drug which is broadly applicable, i.e. has no contraindication, can be given in all forms of stroke and already in the ambulance, is safe, i.e. bears no risk to cause secondary bleeding, is effective, i.e. reduces the brain infarct, increases survival and improves neurological outcomes for patients, has a different mechanism of action, i.e. is directly neuroprotective. Our therapeutic principle, discovered in the course of the ERC-ADG RadMed fulfils all above criteria and is also commercially an innovative approach because we reduce the risk by developing only a single compound by here combining three compounds that target the same disease mechanism but at different points. We thereby expect to dramatically reduce the likelihood risk of failure in our post-proof of concept (PoC) clinical development and commercialisation process. We here propose to conduct the final step, the PoC, before a first-in-man study in stroke. Our PoC plan has three major objectives: To complete an IPR FTPO and Foreground analysis, to chose the optimal compounds and complete phase III pre-clinical to provide PoC for a first-in-man trial in stroke, to then allow the work-out of a complete business plan including competitive analysis, development strategy, and commercial/business development strategy.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores